Source: International Congress 2019 – Evaluation of basic science in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Yavari Ramsheh (Leicester, United Kingdom), K. Haldar (Leicester, United Kingdom), M. Barer (Leicester, United Kingdom), L. Ziegler-Heitbrock (Gauting, Germany), I. Gut (Barcelona, Spain), D. Singh (Manchester, United Kingdom), C. Brightling (Leicester, United Kingdom). Association between COPD bronchial brush microbiome-determined ?Proteobacteria:Firmicutes (G:F) ratio and GOLD grade and symptoms. 1703

Member's Comments

No comment yet.

Related content which might interest you: LSC - 2020 - Could the overweight influence bronchiectasis (B) exacerbations frequency (EF)? Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples Source: Eur Respir J 2005; 26: Suppl. 49, 595s Year: 2005 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Quantitative analysis of potentially pathogenic microbes (PPMs) in the induced sputum of non-smoker COPD (NS-COPD) subjects Source: International Congress 2016 – Clinical and microbiological aspects of infections in COPD patients Year: 2016 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Holding chamber (Spacer) - A potential harbor of pathogenic bacteria Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Heterogeneity of group D in the new GOLD classification of COPD Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 LATE-BREAKING ABSTRACT: Fixed ratio (FR) or lower limit of normality (LLN) in the diagnosis of airway obstruction (AO): Data from the E-DIAL study (Early DIAgnosis of obstructive Lung disease) Source: International Congress 2016 – Prevalence of obstructive airway diseases, methods of diagnosis, and lung function testing Year: 2016 Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 COPD GOLD stage 1: Is it really a disease? Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Changes in bronchial mucous membrane depending on the stage of COPD (I, II) Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Late Breaking Abstract - Adherence to GOLD recommendations in Italian COPD patients stratified by GOLD groups A–D: The MISTRAL study Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017